Actively Recruiting
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Led by University Hospital, Strasbourg, France · Updated on 2025-12-24
70
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) provide anticoagulation through their anti-Xa and anti-IIa activity. This anti-IIa activity can lead to an overestimation of argatroban's activity when switching to an anti-IIa anticoagulant such as argatroban. This situation can be critical because argatroban is generally administered following heparin therapy due to suspected heparin-induced thrombocytopenia. Therefore, there is both a significant thrombotic risk induced by the underlying condition and a hemorrhagic risk induced by the anticoagulation. For this reason, it is important to be able to accurately monitor the anti-IIa activity of argatroban. To date, the test used to determine the anti-IIa activity of argatroban at the Hematology Laboratory of the Strasbourg University Hospitals (HUS) is a modified thrombin time (with a calibration curve adapted for argatroban). When switching between several molecules with anti-IIa activity, this test does not allow for the differentiation of the anti-IIa activity attributable to each anticoagulant. There are no data in the literature to determine whether heparins interfere with this test, and if so, its extent.
CONDITIONS
Official Title
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (≥ 18 years)
- Patient anticoagulated with UFH or LMWH
- Sample sent to the Hematology Laboratory of the University Hospitals of Strasbourg (HUS) and analyzed for measurement of the anti-Xa activity of an anticoagulant in routine care
You will not qualify if you...
- Patient receiving an anticoagulant other than UFH or LMWH
- Insufficient sample volume
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Agathe HERB, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here